Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 48
HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Dong Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 23
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
Liang Shen, Bo Wang, ShaoPeng Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 922-951
Closed Access | Times Cited: 11
Degraders in epigenetic therapy: PROTACs and beyond
Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1464-1499
Open Access | Times Cited: 10
Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors
G. Sivaiah, M.S. Raghu, S. Prasad, et al.
Journal of Molecular Structure (2024) Vol. 1309, pp. 138223-138223
Closed Access | Times Cited: 9
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Epigenetic Modifications in Cancer Etiology, Diagnosis and Therapy
Tajudeen Yahaya, Emmanuel B. John, Asanka Sudeshini Hewage, et al.
Asian Journal of Biological Sciences (2025) Vol. 18, Iss. 2, pp. 516-532
Closed Access
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy
Ekta Shirbhate, Vaibhav Singh, Rakesh Kore, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024)
Xingyou Mo, Devendra Pratap Rao, Kirandeep Kaur, et al.
Molecules (2024) Vol. 29, Iss. 19, pp. 4770-4770
Open Access | Times Cited: 5
Epigenetic regulation of tumor-immune symbiosis in glioma
Yang Liu, Heba Ali, Fatima Khan, et al.
Trends in Molecular Medicine (2024) Vol. 30, Iss. 5, pp. 429-442
Open Access | Times Cited: 4
Co‐delivery Nano System of MS‐275 and V‐9302 Induces Pyroptosis and Enhances Anti‐Tumor Immunity Against Uveal Melanoma
Hong Ren, Zhenkai Wu, Jia Tan, et al.
Advanced Science (2024) Vol. 11, Iss. 31
Open Access | Times Cited: 4
Targeting histone deacetylase 6 (HDAC6) to enhance radiation therapy in meningiomas in a 2D and 3D in vitro study
Juri Na, Shahana Shaji, C. Oliver Hanemann
EBioMedicine (2024) Vol. 105, pp. 105211-105211
Open Access | Times Cited: 4
Acetyl-CoA metabolism as a therapeutic target for cancer
Guo Chen, Banghe Bao, Cheng Yang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115741-115741
Open Access | Times Cited: 13
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Rui Han, Changquan Ling, Yuqian Wang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer
Shaojun Liu, Zhaohui Wang, Lei Hu, et al.
Translational Oncology (2024) Vol. 45, pp. 101982-101982
Open Access | Times Cited: 3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Structure, functions, and recent advances in the development of SIRT2 inhibitors
Junxin Xue, Xuben Hou, Hao Fang
Pharmaceutical Science Advances (2023) Vol. 1, Iss. 2, pp. 100010-100010
Open Access | Times Cited: 9
A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance
Lei Sun, Arabella Wan, Shijia Yan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 223-240
Open Access | Times Cited: 8
Synthesis of a COF-on-MOF hybrid nanomaterial for enhanced colorimetric biosensing
Haojie Xie, Lin Wang, Xiaomeng Yu, et al.
Talanta (2024) Vol. 274, pp. 126071-126071
Closed Access | Times Cited: 2
Multimechanism biological profiling of tetrahydro-β-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease
Ting Liang, Shiru Liu, Baiyun Dang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116624-116624
Closed Access | Times Cited: 2
Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer
Shuting Jia, Yuye Jia, Sufang Liang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 110, pp. 117827-117827
Closed Access | Times Cited: 2
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma
Maryam Safari, Luigi Scotto, Agnès Basseville, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Posttranslational modifications of E2F family members in the physiological state and in cancer: Roles, mechanisms and therapeutic targets
Mingyang Sun, Yitong Ji, Guo‐Jun Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117147-117147
Open Access | Times Cited: 2
Simultaneous Inhibition of FLT3 and HDAC by Novel 6-Ethylpyrazine-2-Carboxamide Derivatives Provides Therapeutic Advantages in Acute Myelocytic Leukemia
Yingjie Chang, Xue Li, Yue Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116847-116847
Closed Access | Times Cited: 2
Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency
Yuan Jiang Pan, Haodong Hou, Bo Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115879-115879
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top